Vaxart, Inc. (VXRT)
0.36
0.00 (0.00%)
USD |
OTCM |
Nov 19, 16:00
Vaxart Enterprise Value : 34.76M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 34.76M |
| November 18, 2026 | 33.54M |
| November 17, 2026 | 33.54M |
| November 16, 2026 | 35.17M |
| November 13, 2026 | 36.63M |
| November 12, 2026 | 37.19M |
| November 11, 2026 | 35.97M |
| November 10, 2026 | 35.24M |
| November 09, 2026 | 37.19M |
| November 06, 2026 | 37.19M |
| November 05, 2026 | 35.97M |
| November 04, 2026 | 44.50M |
| November 03, 2026 | 44.50M |
| November 02, 2026 | 46.97M |
| October 30, 2026 | 51.82M |
| October 29, 2026 | 50.50M |
| October 28, 2026 | 46.45M |
| October 27, 2026 | 44.26M |
| October 26, 2026 | 45.72M |
| October 23, 2026 | 46.94M |
| October 22, 2026 | 54.50M |
| October 21, 2026 | 62.78M |
| October 20, 2026 | 66.44M |
| October 19, 2026 | 62.90M |
| October 16, 2026 | 57.35M |
| Date | Value |
|---|---|
| October 15, 2026 | 57.91M |
| October 14, 2026 | 58.52M |
| October 13, 2026 | 58.30M |
| October 12, 2026 | 54.23M |
| October 09, 2026 | 52.89M |
| October 08, 2026 | 52.91M |
| October 07, 2026 | 52.30M |
| October 06, 2026 | 53.34M |
| October 05, 2026 | 49.38M |
| October 02, 2026 | 53.52M |
| October 01, 2026 | 54.25M |
| September 30, 2026 | 56.69M |
| September 29, 2026 | 57.89M |
| September 28, 2026 | 59.73M |
| September 25, 2026 | 59.02M |
| September 24, 2026 | 58.32M |
| September 23, 2026 | 65.07M |
| September 22, 2026 | 66.20M |
| September 21, 2026 | 68.04M |
| September 18, 2026 | 66.58M |
| September 17, 2026 | 69.96M |
| September 16, 2026 | 63.67M |
| September 15, 2026 | 65.12M |
| September 14, 2026 | 67.55M |
| September 11, 2026 | 66.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 461.25M |
| Amgen, Inc. | 278.17B |
| Anika Therapeutics, Inc. | 159.06M |
| BioCryst Pharmaceuticals, Inc. | 2.327B |
| Imunon, Inc. | 6.407M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.69M |
| Revenue (Quarterly) | 10.62M |
| Total Expenses (Quarterly) | 28.31M |
| EPS Diluted (Quarterly) | -0.0728 |
| Gross Profit Margin (Quarterly) | 88.02% |
| Profit Margin (Quarterly) | -166.6% |
| Earnings Yield | 33.83% |
| Operating Earnings Yield | 34.60% |
| Normalized Earnings Yield | 33.83 |